Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Acrivon Therapeutics (Nasdaq: ACRV) approved an inducement equity award under its 2023 Inducement Plan, consistent with Nasdaq Rule 5635(c)(4). One employee received stock options to purchase 111,150 shares at the May 15, 2026 Nasdaq closing price, with time-based vesting tied to continued employment.
Positive
- None.
Negative
- None.
News Market Reaction – ACRV
In the May 18 session, ACRV declined 6.78%, reflecting a notable negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Q1 2026 earnings | Positive | +0.0% | Reported Q1 loss but solid cash runway and promising ACR-368, ACR-2316 data. |
| Apr 17 | AACR preclinical data | Positive | +4.5% | Announced AACR posters showing strong synergies and broad development opportunities. |
| Apr 15 | Inducement grant | Neutral | +0.0% | Granted stock options to one employee under inducement plan with standard terms. |
| Mar 19 | FY 2025 earnings | Positive | +3.7% | Reported FY 2025 results and strong 52% response in serous endometrial cancer. |
| Mar 17 | Preclinical AP3 data | Positive | -1.2% | Detailed AP3-guided combinations with checkpoint inhibitors and ADC payloads. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Stock has generally reacted positively to clinical and earnings updates, while similar inducement grants have seen flat trading.
Over recent months, Acrivon has focused on advancing its AP3-driven oncology pipeline and maintaining liquidity. Earnings on Mar 19 and May 13 highlighted net losses around $19.0M but cash supporting operations into 2027, alongside a 52% response rate for ACR-368 in serous endometrial cancer. Multiple AACR-related data updates on ACR-368 and ACR-2316 showed strong preclinical synergies and early clinical activity. Prior inducement grants, like the Apr 15 option award, saw no notable price reaction, aligning with today’s routine compensation-focused news.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
stock options financial
exercise price financial
nasdaq global market financial
inducement plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced that the company approved a grant of equity award under its 2023 Inducement Plan to one employee. The equity award was granted in the form of stock options and has a grant date of May 15, 2026.
The employee received an aggregate of options to purchase 111,150 shares of Acrivon common stock. The stock options have an exercise price per share equal to the closing price of Acrivon’s common stock on the Nasdaq Global Market on the date of grant. The stock options will vest
The inducement grants were approved by Acrivon’s Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).
About Acrivon Therapeutics
Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.
Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment.
In addition to ACR-368, Acrivon is also leveraging its proprietary Generative AI-driven Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company’s second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1 trial of ACR-2316 is advancing, with weekly dosing regimens established. Initial data has shown a favorable tolerability profile limited to transient, mechanism-based hematological adverse events, predominantly neutropenia and initial clinical activity across AP3-selected solid tumor types, including PRs in endometrial cancer, as well as SCLC and sqNSCLC, two tumor types which have not shown sensitivity to other clinical WEE1 or PKMYT1 inhibitors currently in development. In addition, the company is advancing ACR-6840, and other potential development candidates, targeting CDK11.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.
Investor and Media Contacts:
Adam D. Levy, Ph.D., M.B.A.
alevy@acrivon.com
Alexandra Santos
asantos@wheelhouselsa.com
